International Collaborative Gaucher Group (ICGG) Gaucher Registry
The ICGG Gaucher Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Gaucher disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The objectives of the Registry are: - To enhance the understanding of the variability, progression, and natural history of Gaucher disease with the ultimate goal of better guiding and assessing therapeutic interventions; - To provide the Gaucher medical community with recommendations for monitoring patients and to provide reports on patient outcomes to help optimize patient care; and - To evaluate the long-term effectiveness of Cerezyme.
Stanford is now accepting new patients for this trial. Please contact SPECTRUM at for more information.
Ages Eligible For Study:
- All patients with a confirmed diagnosis of Gaucher disease are eligible for inclusion in the Registry. Confirmed diagnosis is defined as a documented ?-glucocerebrosidase deficiency and/or mutation in the ?-glucocerebrosidase gene. - For all patients, appropriate patient authorization will be obtained.
Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305